European Commission approve Odomzo (formerly LDE225)

Novartis announce approval of Odomzo (formerly LDE225).

The treatment is for adult patients with locally advanced basal cell carcinomas, who are not amenable to curative surgery.

Reinherd Dummer, MD, Professor and Vicechairman, Department of Dermatology at the University of Zurich quotes "The approval of Odomzo brings new hope in the form of a non-invasive option to help treat this disfiguring and potentially life-threatening disease. 

For further information about the treatment go to Novartis announcement.

 Originally produced by Professor P. A. Farndon, Clinical Geneticist, Jim Costello (deceased) and Margaret Costello.  We are reliant on a team of medical advisors for the clinical content of the website. We are grateful for their continuing support. 
Gorlin Syndrome Group is Registered Charity in the UK - No 1096361 
Gorlin Syndrome community on HealthUnlocked
website security